From the founding director

In the CII, we tackle well known diseases, such as HIV/AIDs, diabetes and colitis, a variety of blood disorders, and diseases those that have historically received limited attention by governments, funding agencies and the world’s media (the ‘neglected diseases’ of poverty).  We provide an intimate link between Biology and Medicine, rarely seen in long-established medical schools, and our research strategy is designed to ensure that we maximise the quality and impact of our research.

Funding from the University, the Hull York Medical School and charitable foundations has provided the infrastructure required to support world-class research, and our research facilities, including for pathogen research, are second to none. The technological base available to us, in a range of core facilities across campus, rivals that available anywhere in the UK, particularly for imaging-based research. With our local NHS partners, we have established the thriving York Clinical Research Facility, providing access to clinical samples through a dedicated Tissue Bank and allowing us to conduct human volunteer studies on both the University and Hospital sites. We have appointed rising stars to many of our core academic positions, each with proven excellence in their discipline, yet with an appetite for inter-disciplinary research, and have an ambitious plan to extend the breadth of our translational research through new clinical academic appointments.  We firmly believe that identifying common threads between disparate diseases can provide new insights and a synergy rarely attainable in highly disease-focussed centres.  

Finally, we have fully exploited the ‘without walls’ approach that is a feature of York, to extend our research beyond traditional boundaries. Few medical research centres of our size could boast of interactions with structural biologists, plant molecular biologists, computer scientists and public health specialists! The strategy is already paying dividends.  In the 10 years since CII opened its doors, we have won over £25M of external research funding, including multiple large programme-style grants and Investigator Awards, and our translational research is bearing fruit: we have identified a new lead compound for treating sleeping sickness; the first leishmaniasis vaccine to be developed in over a decade has finished its Phase 1 first-in-human trial clinical trial; and a range of new HIV interventions are in an advance stage of planning. We have published over 200 peer reviewed articles.  We look forward to making more fundamental discoveries and to exploiting this knowledge for global health benefit.

Professor Paul Kaye
CII founding director

General enquiries